Tavokinogene telsaplasmid - OncoSec Medical

Drug Profile

Tavokinogene telsaplasmid - OncoSec Medical

Alternative Names: DNA IL-12; IL-12 gene therapy; IL-12 plasmid; ImmunoPulse; ImmunoPulse®IL-12; Interleukin-12 gene therapy; intratumoral pIL-12-EP; LipoVIL12; OMS ElectroImmunotherapy™; pIL-12; pIL-12 Electroporation; Tavo

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Biomedical Corporation
  • Developer Fred Hutchinson Cancer Research Center; Massachusetts General Hospital; OncoSec Medical; University of California at San Francisco; University of Washington
  • Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies; Interleukins
  • Mechanism of Action Gene transference; Immunomodulators; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Phase II Breast cancer; Cutaneous T cell lymphoma; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma
  • Preclinical Solid tumours

Most Recent Events

  • 28 Jun 2018 OncoSec Medical plans a phase II neoadjuvant trial of tavokinogene telsaplasmid in combination with nivolumab for Mailgnant melanoma (Combination therapy)
  • 28 Jun 2018 OncoSec Medical plans the phase II KEYNOTE-890 trial of tavokinogene telsaplasmid in combination with pembrolizumab for triple negative Breast cancer (Combination therapy, Second-line therapy or greater)
  • 08 May 2018 OnceSec Medical plans a phase II trial for triple negative Breast cancer (Late stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top